Clinical Trial Update: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase II trial of tipifarnib in HRAS-mutant squamous cell carcinoma of the head and neck, with results publicly posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck
• Thyroid Cancer

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 2 | Status: COMPLETED | Results posted: 2024-07-11